Akouos IPO Presentation Deck

Genetic Medicine Platform Focused on Inner Ear Disorders Attractive Market with High Unmet Need Multimodal Precision Genetic Medicine Platform Potential for Rapid Advancement of Lead Program, AK-OTOF Focused Pipeline Expansion with Access to Multiple Cell Types Value-Add Capabilities and Infrastructure ~466mm people worldwide with disabling hearing loss, including ~34mm children Building a platform that enables development of multiple vector-mediated genetic medicine modalities utilizing proprietary AAVAnc vectors and a novel delivery approach to target a broad range of inner ear disorders AKOUOS AK-OTOF has generated promising preclinical data and has the potential for rapid clinical readout using auditory brainstem response (ABR) as an objective, clinically accepted efficacy endpoint, potentially leading to platform validation Disciplined indication and target selection: suitability for locally delivered AAV, clearly defined mechanism of action/promising in vivo data, potential for rapid clinical readout, and high unmet need / meaningful addressable patient population Developing internal CGMP manufacturing with capabilities to supply vector for clinical trials World-Class Management Team with Team has expertise in auditory anatomy and physiology, otopathology, human genetics, inner ear drug Broad Expertise delivery, gene therapy, and rare disease drug development and commercialization CONFIDENTIAL

View entire presentation